James Kihara - Mar 25, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
PRINCIPAL ACCOUNTING OFFICER
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Mar 25, 2024
Transactions value $
$0
Form type
4
Date filed
3/27/2024, 08:02 PM
Previous filing
Feb 27, 2024
Next filing
Apr 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +14K $0.00 14K Mar 25, 2024 Common Stock 14K $17.84 Direct F1
transaction ACAD Restricted Stock Units Award $0 +8.57K $0.00 8.57K Mar 25, 2024 Common Stock 8.57K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 25, 2025.